The Asia Pacific Non Hodgkin Lymphoma Therapeutics Market would witness market growth of 9.3% CAGR during the forecast period (2023-2030).
Immunotherapeutic approaches have become integral to NHL treatment, including monoclonal antibodies and CAR-T cell therapies. Improved response rates and durable remissions, especially in relapsed or refractory cases. Ongoing research focuses on enhancing the efficacy and expanding the applicability of immunotherapies. They continued developing and optimizing Chimeric Antigen Receptor T-cell (CAR-T) therapies. CAR-T therapies, such as axicabtagene ciloleucel and tisagenlecleucel, have shown remarkable success in certain NHL subtypes, leading to regulatory approvals and increased adoption in clinical practice.
Development of bispecific antibodies designed to target multiple antigens simultaneously. Potential for increased specificity and efficacy, allowing for the simultaneous targeting of different pathways or antigens on cancer cells. Exploration of approved therapies for additional NHL subtypes and treatment settings. Broader patient access and improved treatment options as existing therapies are evaluated in different contexts. Advances in supportive care measures to manage treatment-related side effects.
As China experiences demographic shifts with an aging population, there may be a corresponding increase in the number of individuals diagnosed with NHL. The demand for healthcare services, including cancer diagnosis and treatment, may increase with the growing aging population in China. By 2045, the United Nations estimates that approximately 450 million individuals in China will be 60 or older. Thus, due to the above-mentioned factors, the market will grow significantly in this region.
The China market dominated the Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,137 Million by 2030. The Japan market is showcasing a CAGR of 8.6% during (2023 - 2030). Additionally, The India market would register a CAGR of 10% during (2023 - 2030).
Free Valuable Insights: The Global Non Hodgkin Lymphoma Therapeutics Market is Predict to reach $16.8 Billion by 2030, at a CAGR of 8.4%
Based on Cell Type, the market is segmented into B-Cell Lymphoma and T-Cell Lymphoma. Based on Therapy Type, the market is segmented into Radiation Therapy, Chemotherapy, Targeted Therapy, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd
- Sanofi S.A.
- AbbVie, Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Bristol-Myers Squibb Company
Asia Pacific Non Hodgkin Lymphoma Therapeutics Market Report Segmentation
By Cell Type
- B-Cell Lymphoma
- T-Cell Lymphoma
By Therapy Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
1.4.2 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
1.4.3 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.
Chapter 5. Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type
5.1 Asia Pacific B-Cell Lymphoma Market by Country
5.2 Asia Pacific T-Cell Lymphoma Market by Country
Chapter 6. Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
6.1 Asia Pacific Radiation Therapy Market by Country
6.2 Asia Pacific Chemotherapy Market by Country
6.3 Asia Pacific Targeted Therapy Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country
7.1 China Non Hodgkin Lymphoma Therapeutics Market
7.1.1 China Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.2 China Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2 Japan Non Hodgkin Lymphoma Therapeutics Market
7.2.1 Japan Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.2 Japan Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3 India Non Hodgkin Lymphoma Therapeutics Market
7.3.1 India Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.2 India Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4 South Korea Non Hodgkin Lymphoma Therapeutics Market
7.4.1 South Korea Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.2 South Korea Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.5 Singapore Non Hodgkin Lymphoma Therapeutics Market
7.5.1 Singapore Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.5.2 Singapore Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.6 Malaysia Non Hodgkin Lymphoma Therapeutics Market
7.6.1 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.6.2 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.7 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market
7.7.1 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.7.2 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.6 SWOT Analysis
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 GlaxoSmithKline PLC
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental &Regional Analysis
8.7.4 SWOT Analysis
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Bayer AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
TABLE 1 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 3 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 4 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 5 Asia Pacific B-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 6 Asia Pacific B-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 7 Asia Pacific T-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 8 Asia Pacific T-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Radiation Therapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Radiation Therapy Market by Country, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country, 2023 - 2030, USD Million
TABLE 21 China Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 22 China Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 23 China Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 24 China Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 25 China Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 26 China Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 27 Japan Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 28 Japan Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 29 Japan Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 30 Japan Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 31 Japan Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 32 Japan Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 33 India Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 34 India Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 35 India Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 36 India Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 37 India Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 38 India Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 39 South Korea Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 40 South Korea Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 41 South Korea Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 42 South Korea Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 43 South Korea Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 44 South Korea Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 45 Singapore Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 46 Singapore Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 47 Singapore Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 48 Singapore Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 49 Singapore Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 50 Singapore Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 51 Malaysia Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 Malaysia Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 53 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 54 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 55 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 56 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 57 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
TABLE 58 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
TABLE 59 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
TABLE 60 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
TABLE 61 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
TABLE 62 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
TABLE 63 Key Information – Pfizer, Inc.
TABLE 64 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 65 Key Information – Sanofi S.A.
TABLE 66 Key information – AbbVie, Inc.
TABLE 67 Key Information – Novartis AG
TABLE 68 Key Information – GlaxoSmithKline PLC
TABLE 69 Key Information – Johnson & Johnson
TABLE 70 Key Information – Takeda Pharmaceutical Company Limited
TABLE 71 Key Information – Bayer AG
TABLE 72 Key Information – Bristol-Myers Squibb Company
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Non Hodgkin Lymphoma Therapeutics Market
FIG 4 Porter’s Five Forces Analysis – Non Hodgkin Lymphoma Therapeutics Market
FIG 5 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2022
FIG 6 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Cell Type, 2030
FIG 7 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2030, USD Million
FIG 8 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2022
FIG 9 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Therapy Type, 2030
FIG 10 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2030, USD Million
FIG 11 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Country, 2022
FIG 12 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market share by Country, 2030
FIG 13 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2030, USD Million
FIG 14 Recent strategies and developments: Pfizer Inc.
FIG 15 SWOT Analysis: Pfizer, Inc.
FIG 16 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 17 Swot Analysis: Sanofi S.A.
FIG 18 Swot Analysis: AbbVie, Inc.
FIG 19 SWOT Analysis: Novartis AG
FIG 20 SWOT Analysis: GlaxoSmithKline PLC
FIG 21 SWOT Analysis: Johnson & Johnson
FIG 22 SWOT Analysis:Takeda Pharmaceutical Company Limited
FIG 23 Swot Analysis: Bayer AG
FIG 24 SWOT Analysis: Bristol-Myers Squibb Company